Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting

Executive Summary

Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.

Advertisement

Related Content

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera
Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
UCB’s Cimzia Set To Make A Late Entrance At Psoriasis Party
Pfizer’s Eucrisa Approval By FDA Adds New Dermatology Anchor
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel